TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18922988

Group type: EXPERIMENTAL
Intervention: Hemoglobin target of 9.5 to 11.5 g/dl
Number of subjects: 596

Group type: COMPARATOR
Intervention: Hemoglobin target of 13.5 to 14.5 g/dl
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: High hemoglobin target (13.5 to 14.5 g/dl)
Number of subjects: 596
Study: 15549266

Group type: EXPERIMENTAL
Intervention: Osteoporosis‐related kyphosis (O‐K) group
Number of subjects: 25
Study: 12415439

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study: 10507244

Group type: EXPERIMENTAL
Intervention: 100 mg benfotiamin (S-benzoylthiamine-o-monophosphate, BTMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100 mg thiamine mononitrate (TN)
Number of subjects: 20
Study: 9174677

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg b.i.d.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 248

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 248
Study: 8251730

Group type: EXPERIMENTAL
Intervention: Youjiangzhi capsule
Number of subjects: 61

Group type: COMPARATOR
Intervention: Mai-an Powder
Number of subjects: 61
Study: 3798932

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg i.v. t.i.d.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ranitidine 150 mg i.v. b.i.d.
Number of subjects: 100
Study: 31687178

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 12
Study: 30132960

Group type: EXPERIMENTAL
Intervention: Curcuminoids nanomicelles (80 mg, three times daily, orally) plus mesalamine (3 g/24 hours, orally)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo plus mesalamine (3 g/24 hours, orally)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Curcuminoids nanomicelles plus mesalamine
Number of subjects: 56
Study: 27230934

Group type: EXPERIMENTAL
Intervention: PVAC GOLD catheter
Number of subjects: 40
Study: 24789802

Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Number of subjects: 50
Study: 23208191

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study: 20567009

Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates (90% alendronate, 10% etidronate)
Number of subjects: 154768
Study: 18519002

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg one hour before surgery, then 200 mg every 12 hours for five days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (only PCA morphine)
Number of subjects: 80
Study: 16042732

Group type: EXPERIMENTAL
Intervention: 1.5% glycine irrigation
Number of subjects: 250

Group type: COMPARATOR
Intervention: 5% glucose irrigation
Number of subjects: 250
Study: 12502022

Group type: EXPERIMENTAL
Intervention: YKP10A 400-600 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: YKP10A 100-300 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: YKP10A 700-900 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10748933

Group type: EXPERIMENTAL
Intervention: Lighting direction at +60 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lighting direction at +30 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lighting direction at -60 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lighting direction at 0 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lighting direction at -30 degrees
Number of subjects: 0
Study: 8536780

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 8403135

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms.kg‐1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Diazepam (D)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 42
Study: 4028514

Group type: EXPERIMENTAL
Intervention: Low alcohol content beer (reduced from 336.3 ml to 64.5 ml ethanol/week)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal drinking habits (baseline consumption)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Reduction in alcohol intake
Number of subjects: 46
Study: 31373882

Group type: EXPERIMENTAL
Intervention: 6-week text messaging intervention (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No text messaging (n=20)
Number of subjects: 40
Study: 29529146

Group type: EXPERIMENTAL
Intervention: 15 g milk protein beverage containing 4.2 g leucine (LEU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 15 g mixed protein (milk and soy) beverage containing 1.3 g leucine (CON)
Number of subjects: 22
Study: 27549509

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily) plus standard chemotherapy (cisplatin/etoposide)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily) plus standard chemotherapy (cisplatin/etoposide)
Number of subjects: 157
Study: 23818429

Group type: EXPERIMENTAL
Intervention: Myotubes from physically active donors
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DAGs and ceramides in myotubes
Number of subjects: 18
Study: 21960186

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 603

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 603
Study: 20021991

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 173
Study: 18626531

Group type: EXPERIMENTAL
Intervention: Measles, mumps and rubella (MMR) vaccination at 12 months
Number of subjects: 57
Study: 15978764

Group type: EXPERIMENTAL
Intervention: Low-dose CT (50 mAs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard-dose CT (100 mAs)
Number of subjects: 16
Study: 12449179

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conservative lifestyle strategy
Number of subjects: 71
Study: 10355479

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (jogging at 60-70% of VO2peak, 3 days/week for 35 min/session for 6 weeks)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 13
Study: 8566681

Group type: EXPERIMENTAL
Intervention: Bismuth subcitrate, metronidazole and amoxicillin (TG) for two weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole (OG) for four weeks
Number of subjects: 60
Study: 1798306

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) after 30 minutes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (HBO) after 3 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (before HBO)
Number of subjects: 18
Study: 6248221

Group type: EXPERIMENTAL
Intervention: Cefoperazone (2.0 gm IV infusion over 30 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cefotaxime (2.0 gm IV infusion over 30 minutes)
Number of subjects: 10
Study: 30268803

Group type: EXPERIMENTAL
Intervention: alpha-tACS stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: sham (placebo) stimulation
Number of subjects: 0
Study: 27100317

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus helveticus Lafti L10, 2 × 10 colony‐forming units)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study: 26055391

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 343

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 343
Study: 23361651

Group type: EXPERIMENTAL
Intervention: Art video producing positive and therapeutic 'insight' (Group A)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Art video with 'insight' unfavorable to psychological recovery (Group B)
Number of subjects: 101
Study: 21500992

Group type: COMPARATOR
Intervention: Cetrorelix 0.25 mg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.125 mg/day
Number of subjects: 76
Study: 19224658

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-carbohydrate, high-fibre, low-fat (HC) diet
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 91
Study: 17342998

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 239
Study: 15520052

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11165465

Group type: EXPERIMENTAL
Intervention: Outpatient hospital
Number of subjects: 935

Group type: COMPARATOR
Intervention: Inpatient hospital
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Ambulatory cataract surgery
Number of subjects: 935
Study: 9683360

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (two daily irradiations of 1.15 Gy up to 80.5 Gy in 7 weeks)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Conventional radiotherapy (70 Gy in 7 weeks)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (arm 2)
Number of subjects: 325
Study: 7884745

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 52
Study: 2462581

Group type: EXPERIMENTAL
Intervention: Immunotherapy with cat-hair and dander extract (11 patients)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (11 patients)
Number of subjects: 22
Study: 29845905

Group type: EXPERIMENTAL
Intervention: Bedtime milk snack with 10 g protein (BS10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bedtime milk snack with 30 g protein (BS30)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-energetic placebo (BS0)
Number of subjects: 30
Study: 28695567

Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept (TcTM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tc-99m sulfur colloid (TcSC)
Number of subjects: 52
Study: 26149000

Group type: EXPERIMENTAL
Intervention: Progressive central hypovolemia and correction of hypovolemia (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypervolemia alone (Group II)
Number of subjects: 40
Study: 23778157

Group type: EXPERIMENTAL
Intervention: Carbamazepine (600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacosamide (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19844843

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 18466213

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16631435

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d for 5 weeks)
Number of subjects: 20
Study: 12851531

Group type: EXPERIMENTAL
Intervention: Ximelagatran (60 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 54
Study: 10809270

Group type: EXPERIMENTAL
Intervention: Symptomatic vasospasm risk index
Number of subjects: 283

Group type: COMPARATOR
Intervention: Thickness of subarachnoid clot
Number of subjects: 283

Group type: COMPARATOR
Intervention: Early rise in middle cerebral artery mean flow velocity (MCA-MFV)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Glasgow Coma Scale score <14
Number of subjects: 283

Group type: COMPARATOR
Intervention: Rupture of anterior cerebral or internal carotid artery aneurysm
Number of subjects: 283
Study: 8985764

Group type: EXPERIMENTAL
Intervention: Perioperative nasal application of mupirocin calcium ointment, started on the day before surgery, continued for 5 days, twice daily
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Control group (no mupirocin treatment)
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Perioperative nasal application of mupirocin calcium ointment
Number of subjects: 1796
Study: 1592526

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation for 14 weeks
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 4053509

Group type: EXPERIMENTAL
Intervention: Hand-grip test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cold-pressor test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Baroreceptor stimulation and deactivation by injection of phenylephrine and trinitroglycerine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alteration in carotid baroreceptor activity by a neck chamber
Number of subjects: 39
Study: 31670070

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SM)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (verum SM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham spinal manipulation (sham SM)
Number of subjects: 34
Study: 29931179

Group type: EXPERIMENTAL
Intervention: Intramuscular hydroxocobalamin injections (2000 µg loading dose, 1000 µg at follow-up) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral methylcobalamin (1000 µg daily) for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intramuscular hydroxocobalamin injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral methylcobalamin
Number of subjects: 50
Study: 27136318

Group type: EXPERIMENTAL
Intervention: Carboplatin monotherapy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin combotherapy
Number of subjects: 336
Study: 25264972

Group type: EXPERIMENTAL
Intervention: 1.25 grams/d of omega-3
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 2.50 grams/d of omega-3
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 21925831

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 76
Study: 19363162

Group type: EXPERIMENTAL
Intervention: Discussion of smoking
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Discussion of substance use (smoking, alcohol, drug use)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Discussion of smoking and drug use
Number of subjects: 482
Study: 17346475

Group type: EXPERIMENTAL
Intervention: Partogram
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Standard notes
Number of subjects: 1932
Study: 15752943

Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 to 5.0 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 to 80 mg/day)
Number of subjects: 40
Study: 12022434

Group type: EXPERIMENTAL
Intervention: Plasma retinol-binding protein (RBP) measurement
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Measurement of plasma RBP by radial immunodiffusion
Number of subjects: 236
Study: 10505802

Group type: EXPERIMENTAL
Intervention: Membrane with anorganic bovine bone (T)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Membrane alone (C)
Number of subjects: 11
Study: 9183422

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 microgram.kg‐1 with bupivacaine 0.25%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram.kg‐1 with bupivacaine 0.25%
Number of subjects: 50
Study: 1758240

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.4 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.6 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.8 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.2 mg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Atracurium 0.4 mg/kg
Number of subjects: 64
Study: 6278919

Group type: EXPERIMENTAL
Intervention: 475 mg iodized oil by mouth
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mineral oil (control)
Number of subjects: 100
Study: 31509796

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 28751063

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) repair
Number of subjects: 134

Group type: COMPARATOR
Intervention: Open Lichtenstein repair (OLR)
Number of subjects: 134
Study: 26755223

Group type: EXPERIMENTAL
Intervention: Culturally relevant asthma education intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 23994316

Group type: EXPERIMENTAL
Intervention: Lateral frontal pole (LFP) and anterior insula (AI) activation during voluntary task selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medial prefrontal cortex (MFC) activation during voluntary task selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LFP and AI activation in response to irrelevant external stimuli
Number of subjects: 0
Study: 22461375

Group type: COMPARATOR
Intervention: Integrated, multi-component, school-based intervention programme including changes in school food environment and physical education classes, educational outreach, behaviour change activities, and a social marketing campaign.
Number of subjects: 4363

Group type: COMPARATOR
Intervention: Integrated, multi-component, school-based intervention programme
Number of subjects: 4363
Study: 20619624

Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 μg
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 μg
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg
Number of subjects: 1073

Group type: EXPERIMENTAL
Intervention: Ciclesonide (all doses)
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Ciclesonide and Placebo
Number of subjects: 1073
Study: 17707045

Group type: EXPERIMENTAL
Intervention: Orchiopexy at age 9 months
Number of subjects: 155

Group type: COMPARATOR
Intervention: Orchiopexy at age 3 years
Number of subjects: 155
Study: 15350708

Group type: EXPERIMENTAL
Intervention: Closed endotracheal suction system (closed suction group; N=41)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Open endotracheal suction system (open suction group; N=37)
Number of subjects: 78
Study: 11194245

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Repaglinide (2 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9681667

Group type: EXPERIMENTAL
Intervention: Eptastigmine without food (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eptastigmine with food (30 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8006396

Group type: EXPERIMENTAL
Intervention: 1.5 MU recombinant interferon alpha 2b (Intron) after steroid withdrawal
Number of subjects: 56

Group type: COMPARATOR
Intervention: 1.5 MU interferon after placebo withdrawal
Number of subjects: 56

Group type: COMPARATOR
Intervention: 5 MU interferon after placebo withdrawal
Number of subjects: 56
Study: 2573379

Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol (T) once daily for one year
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (during the one-month run-in and double-blind period)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Dual therapy (T + D)
Number of subjects: 230
Study: 798469

Group type: EXPERIMENTAL
Intervention: Clopimozide, 24 mg weekly (Study I)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clopimozide, daily mean dose of 2.5 mg (Study III)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clopimozide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clopimozide (weekly administration)
Number of subjects: 12
Study: 31924591

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Balance Trainer
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study: 29260533

Group type: EXPERIMENTAL
Intervention: C+E group (convention + esomeprazole 40 mg/d intravenously for 1 week)
Number of subjects: 45

Group type: COMPARATOR
Intervention: C group (convention treatment only)
Number of subjects: 45
Study: 25149364

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block combined with sciatic nerve block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 50
Study: 23147451

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Alcohol and orange juice combined
Number of subjects: 6
Study: 21641964

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study: 19614946

Group type: EXPERIMENTAL
Intervention: glulisine + OAD
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: glulisine monotherapy
Number of subjects: 387

Group type: COMPARATOR
Intervention: OAD only
Number of subjects: 387
Study: 16791115

Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lamivudine-triphosphate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zidovudine-triphosphate
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HIV-RNA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bilirubin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: BCRP
Number of subjects: 33
Study: 14581931

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 0
Study: 11413348

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 49
Study: 15481762

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 6 g/d
Number of subjects: 6
Study: 8513524

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg diluted in 250 ml dextrose 5% administered 30 min before induction of anaesthesia (Group E)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dextrose 5% infusion (Group P)
Number of subjects: 50